Results 181 to 190 of about 1,192,795 (361)

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Lactiplantibacillus plantarum Lp815 improves sleep and increases urinary GABA in a randomized, double-blind, placebo-controlled study of sleep disturbance. [PDF]

Sci Rep
Grant AD, Erfe MCB, Delebecque CJ, Keller D, Zimmerman NP, Kazaryan A, Oliver PL, Moos J, Luna V, Craft N.   +9 more
europepmc   +1 more source

Sequence effect in Parkinson`s disease: placebo-controlled, four-way crossover study of levodopa and rTMS

, 2008
Suk Yun Kang, Toshiaki Wasaka, Ejaz A. Shamim, Sungyoung Auh, Yoshino Ueki, Grisel Lopez, Tetsuo Kida, Seokha Jin, Mark Hallett   +8 more
openalex   +2 more sources

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Placebo and nocebo in clinical practice: An online cross-sectional survey of healthcare professionals from European countries on views, practices and training needs. [PDF]

PLoS One
O'Keeffe M, Skidmore N, Bagnis A, Bąbel P, Bajcar EA, De Palma A, Evers AWM, Glogan E, Haas JW, Meeuwis SH, Oleszczyk M, Portolés A, Vlaeyen JWS, Mattarozzi K, PANACEA Consortium.   +14 more
europepmc   +1 more source

OP0041 Treatment of primary Sjögren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod

Isabelle Peene, Gwenny M. Verstappen, Joke Deprez, Frans G. M. Kroese, S. Arends, Aaron S. Kelly, L. Vandersarren, E Frances Bowen, Johannes W. G. Jacobs, Paul Meyvisch, Dirk Elewaut, Hendrika Bootsma   +11 more
openalex   +1 more source

Can probiotics prevent acute radiation-induced diarrhoea among cervical cancer patients?: the result from a randomized double-blinded placebo-controlled study

, 2018
Ye Htut Linn, K Khine Thu, Nang Hla Hla Win   +2 more
openalex   +2 more sources

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source

Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF II. [PDF]

Circ Popul Health Outcomes
Girard AA, Mylavarapu U, Komtebedde J, Arnold SV, Solomon SD, Leon MB, Van Veldhuisen DJ, Cutlip DE, Cikes M, Zile MR, Gustafsson F, Lilly SM, Boyle A, Cleland JGF, Kaye DM, Emani S, Gupta DK, Hoendermis ES, Flaherty JD, Muller DW, Kapadia SR, Herrmann HC, Cohen DJ, Shah SJ, Spertus JA.   +24 more
europepmc   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source